Opendata, web and dolomites


MAnufacturing process for Cold-chain Independent VIrosome-based VAccines

Total Cost €


EC-Contrib. €






 MACIVIVA project word cloud

Explore the words cloud of the MACIVIVA project. It provides you a very rough idea of what is the project "MACIVIVA" about.

immunological    formats    experts    intramuscularly    instability    world    molecular    outside    fundamental    protection    modifications    administered    packaging    prone    invasive    physical    dried    radicals    chain    screening    pave    degradation    liquid    shear    administration    immunogens    maciviva    therapeutic    kept    life    oral    degradations    stabilization    scientific    smes    complementary    freeze    solid    self    dosage    susceptible    prior    galenic    inherently    sublingual    prevent    interdisciplinary    42    thermostable    chemical    direct    subcutaneously    enhanced    bioactivity    harbor    motion    reconstitution    upscale    excipients    innovative    forms    water    routes    explore    reconstituted    drying    immune    industrial    powder    manufacturing    vaccines    vaccine    stability    universal    slow    ing    expertise    virosome    formulations    intranasal    refrigerated    prophylactic    easily    careful    usually    insufficient    spray    excellence    shelf    oxygen    cold    storage    generating    hours    nanopharmaceuticals    preserving   

Project "MACIVIVA" data sheet

The following table provides information about the project.


Organization address
address: J H OORTWEG 21
city: LEIDEN
postcode: 2333 CH
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 8˙438˙905 €
 EC max contribution 5˙338˙886 € (63%)
 Programme 1. H2020-EU. (Developing next generation nanomaterials, nanodevices and nanosystems)
 Code Call H2020-NMP-PILOTS-2014
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-05-04   to  2018-11-03


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MYMETICS BV NL (LEIDEN) coordinator 1˙755˙073.00
2    UPPERTON LIMITED UK (NOTTINGHAM) participant 1˙647˙777.00
3    CATALENT U.K. SWINDON ZYDIS LIMITED UK (SWINDON) participant 1˙061˙723.00
4    CHIMERA BIOTEC GMBH DE (DORTMUND) participant 874˙312.00
5    BACHEM AG CH (BUBENDORF) participant 0.00
6    MYMETICS SA CH (EPALINGES) participant 0.00


 Project objective

MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes. Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection. For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust “universal” manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42.


List of deliverables.
MACIVIVA webpage launching Websites, patent fillings, videos etc. 2019-05-30 11:28:43
MACIVIVA communication fact sheet Other 2019-05-30 11:28:50
MACIVIVA logo Other 2019-05-30 11:28:49

Take a look to the deliverables list in detail:  detailed list of MACIVIVA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MACIVIVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MACIVIVA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.

ENF2019 (2019)


Read More  

BASMATI (2015)

Bringing innovAtion by Scaling up nanoMATerials and Inks for printing

Read More  

NanoPilot (2015)

A Pilot Plant for the Production of Polymer based Nanopharmaceuticals in Compliance with GMP

Read More